関節リウマチ (RA) - 2029年までの疫学予測

主要8ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本、オーストラリア) における関節リウマチ (RA) と診断された発症件数は、2019年の389,747件から、2029年の425,455件まで増加し、AGRで0.92％の成長が予測されています。

当レポートでは、主要8ヶ国における関節リウマチ (RA) について調査分析し、危険因子と世界の動向、10年間の疫学予測について、体系的な情報を提供しています。

目次

第1章 目次

第2章 関節リウマチ (RA) ：エグゼクティブサマリー

第3章 疫学

• 疾患の背景
• 危険因子と併存疾患
• 世界の動向と歴史的動向
• 予測手法
• RAの疫学予測
  • RAと診断された発症件数
  • RAと診断された発症件数：性別
  • RAと診断された発症件数：年齢別
  • RAと診断された有病者数
  • RAと診断された有病者数：性別
  • RAと診断された有病者数：年齢別
  • RAと診断された有病者数：重症度別
  • RAの総有病者数
  • RAの総有病者数：性別
  • RAの総有病者数：年齢別
  • RAの総有病者数：重症度別
• 議論
  • 疫学予測の考察
  • 分析の限界
  • 分析の強み

第4章 付録

List of Tables

List of Tables

• Table 1: Summary of Updated Data Types
• Table 2: Risk Factors and Comorbidities for RA

List of Figures

List of Figures

• Figure 1: 8MM, Diagnosed Incident Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019 and 2029
• Figure 2: 8MM, Diagnosed Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019 and 2029
• Figure 3: 8MM, Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019
• Figure 4: 8MM, Diagnosed Prevalence (%) of RA, Both Sexes, Ages ≥18 Years, 2019
• Figure 5: 8MM, Total Prevalence (%) of RA, Both Sexes, Ages ≥18 Years, 2019
• Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of RA
• Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed and Total Prevalent Cases of RA
• Figure 8: 8MM, Diagnosed Incident Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
• Figure 9: 8MM, Diagnosed Incident Cases of RA, N, by Sex, Ages ≥18 Years, 2019
• Figure 10: 8MM, Diagnosed Incident Cases of RA by Age, N, Both Sexes, 2019
• Figure 11: 8MM, Diagnosed Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
• Figure 12: 8MM, Diagnosed Prevalent Cases of RA, N, by Sex, Ages ≥18 Years, 2019
• Figure 13: 8MM, Diagnosed Prevalent Cases of RA by Age, N, Both Sexes, 2019
• Figure 14: 8MM, Diagnosed Prevalent Cases of RA by Severity, N, Both Sexes, Ages ≥18 Years, 2019
• Figure 15: 8MM, Total Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
• Figure 16: 8MM, Total Prevalent Cases of RA, N, by Sex, Ages ≥18 Years, 2019
• Figure 17: 8MM, Total Prevalent Cases of RA by Age, N, Both Sexes, 2019
• Figure 18: 8MM, Total Prevalent Cases of RA by Severity, N, Both Sexes, Ages ≥18 Years, 2019

Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. The condition manifests itself in multiple joints in the body (Mayo Clinic, 2019; Centers for Disease Control and Prevention, 2020). RA is the result of an immune response in which the body's immune system attacks its own healthy cells, especially the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response (Centers for Disease Control and Prevention, 2020). The disease can lead to premature mortality, disability, and decreased quality of life due to bone erosion and joint deformity (Brooks, 2006; Centers for Disease Control and Prevention, 2020).

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast. GlobalData epidemiologists used sources that confirmed RA cases based on the American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06, in order to ensure a uniform case definition across markets. The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent (total and diagnosed) cases of RA in the 8MM, segmented by age, sex, and severity.

The following data describes epidemiology of RA. In the 8MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of RA from 389,747 cases in 2019 to 425,455 cases in 2029, at an AGR of 0.92% over the forecast period. The diagnosed prevalent cases of RA in the 8MM will increase from 4,605,338 cases in 2019 to 5,093,229 cases in 2029, at an AGR of 1.06% over the forecast period. The total prevalent cases of RA in the 8MM will increase from 6,308,268 cases in 2019 to 6,980,823 cases in 2029, at an AGR of 1.07% over the forecast period. RA is more common in women, and the incidence and prevalence of RA typically increases with advancing age. These trends are reflected in GlobalData's forecast for the diagnosed incident and prevalent (total and diagnosed) cases for the 8MM.

Scope

• The Rheumatoid Arthritis (RA) Epidemiology Report provides an overview of the risk factors and global trends of IPF in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
• The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent cases of RA (total and diagnosed) segmented by sex and age (ages ≥18 years). The prevalent cases of RA (total and diagnosed) are also segmented by severity (mild, moderate, and severe). In addition, the model corresponding to this report includes prevalent cases of RA (total and diagnosed) segmented by comorbidities (depression, cardiovascular disease, cancer, gastrointestinal ulcer, hypertension, hyperlipidemia, obesity, osteoporosis, osteoarthritis, chronic obstructive pulmonary disease, and asthma).
• The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Rheumatoid Arthritis Epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global RA market.
• Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RA therapeutics in each of the markets covered.
• Understand magnitude of RA population by severity at diagnosis.

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

• 2.1 Catalyst
• 2.2 Related Reports
• 2.3 Upcoming Reports

3 Epidemiology

• 3.1 Disease Background
• 3.2 Risk Factors and Comorbidities
• 3.3 Global and Historical Trends
• 3.4 Forecast Methodology
  • 3.4.1 Sources
  • 3.4.2 Forecast Assumptions and Methods
• 3.5 Epidemiological Forecast for RA (2019-2029)
  • 3.5.1 Diagnosed Incident Cases of RA
  • 3.5.2 Sex-Specific Diagnosed Incident Cases of RA
  • 3.5.3 Age-Specific Diagnosed Incident Cases of RA
  • 3.5.4 Diagnosed Prevalent Cases of RA
  • 3.5.5 Sex-Specific Diagnosed Prevalent Cases of RA
  • 3.5.6 Age-Specific Diagnosed Prevalent Cases of RA
  • 3.5.7 Diagnosed Prevalent Cases of RA by Severity
  • 3.5.8 Total Prevalent Cases of RA
  • 3.5.9 Sex-Specific Total Prevalent Cases of RA
  • 3.5.10 Age-Specific Total Prevalent Cases of RA
  • 3.5.11 Total Prevalent Cases of RA by Severity
• 3.6 Discussion
  • 3.6.1 Epidemiological Forecast Insight
  • 3.6.2 Limitations of the Analysis
  • 3.6.3 Strengths of the Analysis

4 Appendix

• 4.1 Bibliography
• 4.2 Primary Research - KOLs Interviewed for this Report
• 4.3 About the Authors
  • 4.3.1 Epidemiologist
  • 4.3.2 Reviewers
  • 4.3.3 Global Director of Therapy Analysis and Epidemiology
  • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
• 4.4 About GlobalData
• 4.5 Contact Us
• 4.6 Disclaimer